⌘K
Loading ticker…
Ultragenyx Pharmaceutical Inc. · Healthcare · Pharmaceutical Products
As of 2026-06-26, Ultragenyx Pharmaceutical Inc. (RARE) has a 3-month relative strength percentile of 90 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 54. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 5.1%, relative volume 8.93×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 90, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Strong relative strength with attention running hot versus its own recent norm. The trend is intact but well-noticed; elevated retail attention has historically been associated with softer forward returns. Context, not a call.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
RARE is held by 9 ETFs as of Mar 2026. Top owner: XBI at 0.88% weight, $65M notional. Top 3 carry $171M.
Top 9 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| XBIState Street SPDR S&P Biotech ETF | 0.88% | $65M |
| VTIVanguard Total Stock Market ETF | 0.00% | $62M |
| VBVanguard Small Cap ETF | 0.03% | $44M |
| VBKVanguard Small-Cap Growth ETF | 0.06% | $25M |
| VXFVanguard Extended Market ETF | 0.03% | $23M |
| IWFiShares Russell 1000 Growth ETF | 0.01% | $8M |
| IWRiShares Russell Midcap ETF | 0.02% | $7M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $3M |
| IWBiShares Russell 1000 ETF | 0.00% | $1M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RARE Jan avg: -0.75% median: 0.06% win: 50% σ: 5.46% n: 4 2022-04-12 → 2026-05-29 | RARE Feb avg: 3.08% median: -1.05% win: 25% σ: 9.51% n: 4 2022-04-12 → 2026-05-29 | RARE Mar avg: -11.42% median: -10.15% win: 0% σ: 2.83% n: 4 2022-04-12 → 2026-05-29 | RARE Apr avg: 2.94% median: 7.65% win: 60% σ: 12.34% n: 5 2022-04-12 → 2026-05-29 | RARE May avg: -8.40% median: -5.64% win: 20% σ: 16.97% n: 5 2022-04-12 → 2026-05-29 | RARE Jun avg: 7.47% median: 4.62% win: 75% σ: 14.28% n: 4 2022-04-12 → 2026-05-29 (current) | RARE Jul avg: -8.14% median: -8.61% win: 25% σ: 14.16% n: 4 2022-04-12 → 2026-05-29 | RARE Aug avg: 2.65% median: -0.41% win: 50% σ: 18.91% n: 4 2022-04-12 → 2026-05-29 | RARE Sep avg: -4.51% median: -2.63% win: 25% σ: 5.96% n: 4 2022-04-12 → 2026-05-29 | RARE Oct avg: 0.96% median: -1.50% win: 25% σ: 9.92% n: 4 2022-04-12 → 2026-05-29 | RARE Nov avg: -1.67% median: -3.08% win: 50% σ: 8.82% n: 4 2022-04-12 → 2026-05-29 | RARE Dec avg: 1.31% median: 5.71% win: 50% σ: 29.27% n: 4 2022-04-12 → 2026-05-29 |